EPIAXIS THERAPEUTICS ANNOUNCES THE APPOINTMENT OF THREE NEW NON-EXECUTIVE DIRECTORS
Following recent advancements in its preclinical and commercial development, EpiAxis has appointed Professor Pamela Munster, a highly regarded medical oncologist in the field of metastatic breast cancer and epigenetics; Keir J Loiacono, an oncology focused business...
EPIAXIS THERAPEUTICS ANNOUNCES SEARCH FOR STRATEGIC PARTNERS FOR LEADERSHIP IN EPIGENETIC CONTROL OF METASTATIC CANCER
EpiAxis has appointed The Sage Group to lead the partnering program for its peptide candidates which modulate the epigenetic control of metastatic cancer. SYDNEY, AUSTRALIA, August 12, 2019 /EINPresswire.com/ -- Following a strategic review of its clinical and...
EPIAXIS EXPANDS ITS PHASE 1 METASTATIC BREAST CANCER TRIAL
EpiAxis Therapeutics, a University of Canberra spin out company, has expanded its clinical trial program to include two additional recruitment centres for its Phase 1b metastatic breast cancer program. Those centres are open for patient recruitment at the Southern...
There is currently no therapy to fight recurrent, metastatic breast cancer, which is the major source of death in women with breast cancer. Furthermore, current first-line treatments have extensive side-effects.We are determined to fix that.
Professor Sudha Rao
Founder at EpiAxis Therapeutics